Table 2

Endothelial function and inflammation in nondiabetic subjects and subjects with type 1 diabetes

EuglycemiaHypoglycemia
BaselineTestRecovery+6 h+24 hBaselineTestRecovery+6 h+24 h
Nondiabetic subjects
    tPA (ng/ml)7.37 ± 8.16.80 ± 7.9*6.44 ± 7.5*6.99 ± 9.38.51 ± 7.810.96 ± 11.812.55 ± 16.79.10 ± 10.2*9.83 ± 12.011.45 ± 11.6
    vWF (iU/ml)0.81 ± 0.30.76 ± 0.30.78 ± 0.20.80 ± 0.30.85 ± 0.30.82 ± 0.30.81 ± 0.30.89 ± 0.50.90 ± 0.30.89 ± 0.3
    CD40 (%)1.51 ± 1.42.23 ± 3.22.40 ± 3.20.84 ± 0.72.06 ± 1.01.92 ± 2.21.47 ± 1.11.55 ± 1.51.98 ± 2.43.13 ± 2.3
    sCD40L (ng/ml)2.68 ± 3.12.41 ± 2.82.40 ± 2.9*2.63 ± 2.93.08 ± 3.32.88 ± 3.32.80 ± 3.22.55 ± 3.22.72 ± 3.32.79 ± 3.2
    IL-6 (pg/ml)0.86 ± 0.51.06 ± 1.21.05 ± 1.05.98 ± 4.61.23 ± 0.90.72 ± 0.40.92 ± 0.51.62 ± 1.24.37 ± 4.31.00 ± 0.9
    hsCRP (ng/ml)1.04 ± 1.11.22 ± 1.91.18 ± 1.91.24 ± 1.61.31 ± 1.51.83 ± 1.51.81 ± 1.91.56 ± 1.3*1.69 ± 1.21.90 ± 1.6
Subjects with type 1 diabetes
    tPA (ng/ml)15.25 ± 30.217.70 ± 31.115.99 ± 27.522.13 ± 46.220.86 ± 34.818.12 ± 30.120.55 ± 36.117.69 ± 31.118.37 ± 32.622.98 ± 40.3
    vWF (iU/ml)0.91 ± 0.20.85 ± 0.2*0.91 ± 0.30.85 ± 0.2*0.99 ± 0.20.93 ± 0.20.95 ± 0.20.91 ± 0.20.90 ± 0.21.02 ± 0.2
    CD40 (%)3.64 ± 2.03.65 ± 1.84.14 ± 2.53.97 ± 2.34.35 ± 2.03.69 ± 3.45.54 ± 4.43.36 ± 3.04.88 ± 2.44.70 ± 2.8
    sCD40L (ng/ml)2.86 ± 2.82.85 ± 2.82.84 ± 2.82.91 ± 2.93.25 ± 3.23.36 ± 2.93.41 ± 3.23.10 ± 2.9*3.05 ± 2.8*3.44 ± 2.9
    IL-6 (pg/ml)0.69 ± 0.51.38 ± 1.91.58 ± 1.82.25 ± 2.81.19 ± 1.21.21 ± 1.71.15 ± 1.5)1.76 ± 1.53.10 ± 4.91.96 ± 2.2
    hsCRP (ng/ml)2.52 ± 3.12.20 ± 2.92.32 ± 2.81.92 ± 1.83.40 ± 3.62.84 ± 3.22.72 ± 3.12.70 ± 3.22.89 ± 3.32.34 ± 2.8
  • Data are means ± SD.

  • *Significant decrease from baseline (P < 0.05);

  • †significant increase from baseline (P < 0.05);

  • ‡significant difference between hypoglycemia and euglycemia (P < 0.05).